Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).

[1][2] A clinical trial for relapsed adult acute lymphoblastic leukemia (ALL) has reported initial results.

[3] Early results from a phase II trial for Diffuse large B-cell lymphoma (DLBCL) were encouraging.

July 2015 : Both phase III trials (EMBODY1/2) for SLE failed to meet their primary endpoint.

"Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system"[6] via a process called trogocytosis.